{"contentid": 488270, "importid": NaN, "name": "Psychedelics specialist starts Phase IIa test of lead candidate", "introduction": "A Phase IIa study has been initiated for RL-007, lead candidate of Recognify Life Sciences, part of Berlin-based biotech Atai Life Sciences.", "content": "<p>A Phase IIa study has been initiated for RL-007, lead candidate of Recognify Life Sciences, part of Berlin, Germany-based biotech Atai Life Sciences.</p>\n<p>Recognify is focused on developing treatments for cognitive impairment, beginning with cognitive impairment associated with schizophrenia (CIAS).</p>\n<p>The firm has received investigational new drug (IND) clearance from the US Food and Drug Administration to commence clinical trials in the USA in this indication.</p>\n<p>The Phase IIa study is a single-arm, multiple dose design in people who exhibit CIAS, and it evaluates the effects of the drug on safety and tolerability, electroencephalograms and cognition.</p>\n<p>The firm hopes the study will enable it to progress the product towards a Phase IIb efficacy study in this area of high medical need.</p>\n<h2>Atai progress</h2>\n<p>Atai, a German CNS specialist with an office in New York, USA, recently announced the successful closing of a $157 million series D financing round.</p>\n<p>The round was led by existing investors Apeiron Investment Group, the family office of Atai&rsquo;s founder Christian Angermayer, Thiel Capital, and Woodline Partners LP.</p>\n<p>Founded in 2018 to address unmet medical need in the mental health treatment landscape, Atai seeks to acquire, incubate and efficiently develop innovative therapeutics for depression, anxiety, addiction, and other mental health disorders.</p>\n<p>The firm has a focus on psychedelic therapies and other drugs with differentiated safety profiles and therapeutic potential.</p>\n<p>Chief executive Florian Brand said: &ldquo;In a treatment landscape with no effective options, we are determined to progress RL-007 for the treatment of CIAS. We believe that the compound has great potential in CIAS, based upon the promising pro-cognitive profile demonstrated in previous preclinical and clinical studies.&rdquo;</p>", "date": "2021-04-07 14:49:00", "meta_title": NaN, "meta_keywords": "Phase, Life, study, Sciences, Atai, lead, candidate, Recognify, CIAS, specialist, Psychedelics, starts, test, drug, biotech, Berlin-based, part, initiated", "meta_description": "A Phase IIa study has been initiated for RL-007, lead candidate of Recognify Life Sciences, part of Berlin-based biotech Atai Life Sciences.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-07 12:07:41", "updated": "2021-04-07 14:49:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/psychedelics-specialist-starts-phase-iia-test-of-lead-candidate", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "atai_life_sciences_large.png", "image2id": "atai_life_sciences_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Drug Trial, Research", "geography_tag": "Germany, USA", "company_tag": "ATAI Life Sciences, Recognify Life Sciences", "drug_tag": "RL-007", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-07 14:49:00"}